(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 83.19% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Lenz Therapeutics's revenue in 2026 is $12,359,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $518,785,246, with the lowest LENZ revenue forecast at $434,169,616, and the highest LENZ revenue forecast at $682,926,372. On average, 9 Wall Street analysts forecast LENZ's revenue for 2027 to be $1,170,982,287, with the lowest LENZ revenue forecast at $643,556,381, and the highest LENZ revenue forecast at $1,637,735,048.
In 2028, LENZ is forecast to generate $2,514,369,313 in revenue, with the lowest revenue forecast at $1,237,908,129 and the highest revenue forecast at $3,860,018,622.